SHANGHAI, March 6, 2026 /PRNewswire/ -- Jiahui International Cancer Center (JICC) has stabilized a U.S. patient with advanced non‑small cell lung cancer (NSCLC) and Parkinson's disease using ivonescimab, a novel immunotherapy currently available only in China. Continue Reading Dr. Xuan Linli, Chief of Medical Oncology at Jiahui International Cancer Center, stands on the patient’s right. The patient’s daughter, nursing team, medical team, and caregivers are gathered together at Jiahui Internation

BURR RIDGE, Ill., March 6, 2026 /PRNewswire/ -- SkinCure Oncology, the industry leader in providing a comprehensive cancer center model for the delivery of Image-Guided Superficial Radiation Therapy (Image-Guided SRT or IGSRT) for the treatment of nonmelanoma skin cancer (NMSC), presented to dermatology patients and professionals as the GentleCure Experience™, today announced that it has filed suit with co- plaintiffs in United States District Court for the District of Columbia seeking an injunc

A Study shows mutation-resistant antibodies with 269×affinity, a proof point for CEPI’s 100 Days Mission and closing the therapeutic gap for 2.5B people at risk Our AI-designed antibodies that worked against viral variants the model had never seen. And prediction is what you need when the next pandemic pathogen emerges and you have days, not years, to respond” — Dr. Lurong Pan, Founder and CEO of Ainnocence SAN FRANCISCO , CA, UNITED STATES, March 6, 2026 / EINPresswire.com / -- Ainnocence Inc.,

Acquisition positions Servier as a leader in pediatric low-grade glioma and expands its pipeline with programs targeting adult and pediatric cancers with high unmet needs. Transaction represents total equity value of approximately $2.5 billion. SURESNES, France and BRISBANE, Calif., March 6, 2026 /PRNewswire/ -- Servier, an independent international pharmaceutical group governed by a foundation, and Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) ("Day One"), a biopharmaceutical company dedic

GALWAY, Ireland, March 6, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced that MiniMed Group, Inc. (Nasdaq: MMED) will begin trading today on the Nasdaq Global Select Market (Nasdaq) under the ticker symbol "MMED" in connection with its initial public offering ("IPO"). "Today marks an exciting milestone for both MiniMed and Medtronic. Despite a challenging market backdrop shaped by geopolitical uncertainty, the teams successfully executed an ov

NESCONSET, N.Y., March 6, 2026 /PRNewswire/ -- LifeVac LLC announced today that the U.S. Food and Drug Administration (FDA) has granted De Novo classification for LifeVac under 21 CFR 874.5400, formally establishing the device type "suction anti-choking device as a second-line treatment." Continue Reading LifeVac Under the order, LifeVac is classified as a Class II medical device. The FDA defines this device type as one intended to be used, by application of suction, to resolve choking in victim

MILWAUKEE, March 6, 2026 /PRNewswire/ -- Lohman Technologies (), innovator of the FDA-cleared HomECG+ medical-grade home ECG monitoring device, today announced a deepened strategic partnership with Salvo Health (), a leading virtual care platform for GI and metabolic conditions. The effort builds on the successful 2024 collaboration that integrated home monitoring into Salvo's wraparound care model for IBS and IBD GI patients, leveraging heart rate variability (HRV) as an indicator of progress f

WASHINGTON, March 6, 2026 /PRNewswire/ -- The Organization for Social Media Safety today applauded the House Energy and Commerce Committee's approval of H.R. 2657, Sammy's Law, bipartisan legislation that empowers families to use FTC-registered third-party safety software on all major social media platforms to help protect children from the most severe social media harms, including drug dealing, cyberbullying, predation, trafficking, and self-harm content. Sammy's Law enables parents and teens t

Over three quarters of people on Gazyva/Gazyvaro plus standard therapy achieved at least a four-point improvement in SRI-4, a measure that assesses disease severity and symptomsGazyva/Gazyvaro has the potential to become a new standard of care for people living with systemic lupus erythematosus (SLE)If approved, Gazyva/Gazyvaro would be the first Type II anti-CD20 therapy for SLE to directly target B cells, a key driver of inflammation and disease activity1SLE is a potentially life-threatening a

Shining the Spotlight on Expert Insights and Targeted Supplements to Support Imbalanced Hormones in Women FORT LAUDERDALE, Fla., March 6, 2026 /PRNewswire/ -- Women's health is increasingly in the spotlight. A recent McKinsey report from the J.P. Morgan Healthcare Conference suggested that closing the women's health gap could add over $1 trillion to the global economy annually within 15 years. McKinsey senior partner and McKinsey Health Institute leader Lucy Pérez referred to women's health as e